» Articles » PMID: 17207708

HLAMatchmaker: a Molecularly Based Algorithm for Histocompatibility Determination. V. Eplet Matching for HLA-DR, HLA-DQ, and HLA-DP

Overview
Journal Hum Immunol
Date 2007 Jan 9
PMID 17207708
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

This report describes the design of the eplet version of HLAMatchmaker to determine class II compatibility at the structural level. This matching algorithm is based on the hypothesis, developed from molecular modeling of crystallized antigen-antibody complexes, that functional epitopes are represented by patches of surface-exposed nonself-amino acid residues surrounded by residues within a 3-A radius. Patch determinations with a molecular viewer of crystalline structural models downloaded from the Entrez Molecular Modeling Database Web site led to the identification of 44 DRB, 33DQB, 29 DQA, 20 DPB, and 9 DPA unique combinations of polymorphic positions. The residue compositions of these patches were then determined from amino acid sequences. This analysis resulted in a repertoire of 146 DRB, 74 DQB, 58 DQA, 45 DPB, and 19 DPA eplets. In many eplets, the residues are in short linear sequences, but many other eplets have discontinuous sequences of residues that cluster on or near the molecular surface. This analysis has also shown that all serologically defined DR and DQ antigens detectable by monospecific antibodies have unique eplets. Other eplets are present in groups of class II antigens, many of which appear as cross-reacting. The eplet version of HLAMatchmaker should be considered as a hypothetical model for the structural assessment of donor-recipient compatibility and the determination of mismatch acceptability for sensitized patients. This computer algorithm can be downloaded from the HLA Matchmaker Webside at http://tpis.upmc.edu.

Citing Articles

Advancing risk stratification in kidney transplantation: integrating HLA-derived T-cell epitope and B-cell epitope matching algorithms for enhanced predictive accuracy of HLA compatibility.

Niemann M, Matern B, Gupta G, Tanriover B, Halleck F, Budde K Front Immunol. 2025; 16:1548934.

PMID: 40007544 PMC: 11850546. DOI: 10.3389/fimmu.2025.1548934.


Anti-Human Leukocyte Antigen Antibody Detection from Terasaki's Humoral Theory to Delisting Strategies in 2024.

San Segundo D, Comins-Boo A, Lopez-Hoyos M Int J Mol Sci. 2025; 26(2).

PMID: 39859344 PMC: 11766285. DOI: 10.3390/ijms26020630.


Novel Aspects of Immunogenetics and Post-Transplant Events in Kidney Transplantation.

Helantera I, Markkinen S, Partanen J, Hyvarinen K Transpl Int. 2024; 37:13317.

PMID: 39703873 PMC: 11655191. DOI: 10.3389/ti.2024.13317.


Genome-wide meta-analysis associates donor-recipient non-HLA genetic mismatch with acute cellular rejection post-liver transplantation.

Nieuwenhuis L, Li Y, Loza B, Lambeck A, Hu S, Gacesa R Hepatol Commun. 2024; 9(1.

PMID: 39670865 PMC: 11637756. DOI: 10.1097/HC9.0000000000000601.


HLA-EpiCheck: novel approach for HLA B-cell epitope prediction using 3D-surface patch descriptors derived from molecular dynamic simulations.

Amaya-Ramirez D, Devriese M, Lhotte R, Usureau C, Smail-Tabbone M, Taupin J Bioinform Adv. 2024; 4(1):vbae186.

PMID: 39659590 PMC: 11631505. DOI: 10.1093/bioadv/vbae186.


References
1.
Itescu S, TUNG T, Burke E, Weinberg A, Moazami N, Artrip J . Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation. 1998; 98(8):786-93. DOI: 10.1161/01.cir.98.8.786. View

2.
Lobashevsky A, Senkbeil R, Shoaf J, Stephenson A, Skelton S, Burke R . The number of amino acid residues mismatches correlates with flow cytometry crossmatching results in high PRA renal patients. Hum Immunol. 2002; 63(5):364-74. DOI: 10.1016/s0198-8859(02)00371-3. View

3.
Matsuno N, Inoko H, Ando A, Nakatsuji T, Sato T, Itchikawa S . Importance of DQB as an indicator in living-related kidney transplant. Transplantation. 1990; 49(1):208-12. DOI: 10.1097/00007890-199001000-00046. View

4.
Duquesnoy R, Witvliet M, Doxiadis I, de Fijter H, Claas F . HLAMatchmaker-based strategy to identify acceptable HLA class I mismatches for highly sensitized kidney transplant candidates. Transpl Int. 2003; 17(1):22-30. DOI: 10.1007/s00147-003-0641-z. View

5.
Lee K, Wucherpfennig K, Wiley D . Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes. Nat Immunol. 2001; 2(6):501-7. DOI: 10.1038/88694. View